Suppressing the intestinal farnesoid X receptor/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis

• Published in: The Journal of clinical investigation Vol. 131; no. 9
• Main Authors: Wu, Qing, Sun, Lulu, Hu, Xiaomin, Wang, Xuemei, Xu, Feng, Chen, Bo, Liang, Xianyi, Xia, Jialin, Wang, Pengcheng, Aibara, Daisuke, Zhang, Shaofei, Zeng, Guangyi, Yun, Chuyu, Yan, Yu, Zhu, Yicheng, Bustin, Michael, Zhang, Shuyang, Gonzalez, Frank J., Jiang, Changtao
• Format: Journal Article
• Language: English
• Published: United States American Society for Clinical Investigation 01.05.2021
• Subjects: Animals; Atherosclerosis; Atherosclerosis - chemically induced; Atherosclerosis - drug therapy; Atherosclerosis - genetics; Atherosclerosis - metabolism; Ceramides - biosynthesis; Ceramides - genetics; Complications and side effects; Development and progression; Diet, High-Fat - adverse effects; Female; Health aspects; Humans; Hypercholesterolemia; Intestinal Mucosa - metabolism; Male; Mice; Mice, Knockout, ApoE; Phosphodiesterases; Physiological aspects; Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors; Receptors, Cytoplasmic and Nuclear - genetics; Receptors, Cytoplasmic and Nuclear - metabolism; Risk factors; Sphingomyelin Phosphodiesterase - genetics; Sphingomyelin Phosphodiesterase - metabolism; Ursodeoxycholic Acid - analogs & derivatives; Ursodeoxycholic Acid - pharmacology; China; Cardiovascular disease; Cardiology; Vascular Biology; Atherosclerosis

Intestinal farnesoid X receptor (FXR) signaling is involved in the development of obesity, fatty liver disease, and type 2 diabetes. However, the role of intestinal FXR in atherosclerosis and its potential as a target for clinical treatment have not been explored. The serum levels of fibroblast grow...